SOFW SOFWAVE MEDICAL LTD

Sofwave Medical Appoints Medical Aesthetics Industry Expert James Bartholomeusz to the Role of Chief Innovation Officer

Sofwave Medical Appoints Medical Aesthetics Industry Expert James Bartholomeusz to the Role of Chief Innovation Officer

SAN CLEMENTE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced the appointment of James Bartholomeusz to the newly created position of Chief Innovation Officer. Mr. Bartholomeusz is a medical aesthetics expert and industry veteran with more than 20 years of experience. He will lead global product innovation, development, and go-to market strategies for new product launches.

“We are delighted to have James join Sofwave at this important stage of accelerated growth, product innovation and global expansion. His past leadership and track record in developing and launching new products includes driving the innovation and roll-out of groundbreaking body contouring technologies, leading-edge energy-based devices, and sophisticated skin treatment solutions, most notably the world’s first fractional RF device,” noted Louis Scafuri, CEO of Sofwave Medical. “We believe James’ relentless pursuit of innovation and excellence has positioned him at the forefront of the medical aesthetics industry. His past accolades serve as testament to his desire to redefine standards of care with a clear focus on long term patient experience. We look forward to the positive impact of James’ leadership, vision and expertise, as we strive to set new treatment innovation benchmarks in our industry.”

Commenting on his appointment, Mr. Bartholomeusz said, “I am honored to join Sofwave and have been impressed with the rapid adoption, acceptance, and growing reputation of the Company’s innovative SUPERB™ technology. Having helped develop and launch some of the industry’s most popular and effective conventional energy-based skin treatment solutions. I look forward to collaborating with the team to bring the very best, transformative non-invasive skin treatment solutions to the market and accelerate new product launches and market penetration for Sofwave products.”

Mr. Bartholomeusz joins Sofwave after his previous role as chief technology officer (CTO) at Lutronic, where he was responsible for developing and executing an ambitious 5-year product roadmap and growth strategy that included various industry defining products like DermaV before Lutronic was acquired by private equity in August of 2023. Prior to Lutronic Mr. Bartholomeusz served Syneron-Candela as Global Vice President of Product Development.

About Sofwave Medical

 has implemented an innovative approach to wrinkle reduction, lifting and cellulite using its proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology is FDA-cleared to improve facial lines and wrinkles, lifting the eyebrow and lifting lax submental tissue (beneath the chin) and neck tissue, the short-term improvement in the appearance of cellulite, improvement of skin laxity on upper arms and treatment of acne scars, providing physicians with smart yet simple, effective, and safe aesthetic solutions for their patients. Contact: 

Investor Contact:

Brian Ritchie

LifeSci Advisors LLC

(212) 915-2578



EN
12/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SOFWAVE MEDICAL LTD

 PRESS RELEASE

Sofwave to Participate in Jefferies Global Healthcare Conference

Sofwave to Participate in Jefferies Global Healthcare Conference SAN CLEMENTE, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW),  an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Assaf Korner, Chief Financial Officer, will provide a corporate overview and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in New York from June 3-5, 2025. Jefferies Global Healthcare ConferencePresentation Format: Corporate overviewPresentat...

 PRESS RELEASE

Sofwave Medical Reports First Quarter Fiscal 2025 Financial Results an...

Sofwave Medical Reports First Quarter Fiscal 2025 Financial Results and Business Highlights — First quarter revenue of $16.7M, +26% year-over-year growth; IFRS gross margin of 76.3%— First quarter pulse recurring revenue of $7.0M, +49% year-over-year growth— IFRS and non-IFRS operating loss of -$1M and -$0.2M, respectively SAN CLEMENTE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the first quarter of fiscal year 2025, for th...

 PRESS RELEASE

Sofwave’s liftHD Body Contouring Applicator to Debut at the 44th Annua...

Sofwave’s liftHD Body Contouring Applicator to Debut at the 44th Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) 2025 Launch of the liftHD body applicator provides opportunity for next generation non-invasive aesthetic body treatments which improve cellulite and skin laxity appearance in order to achieve SUPERB results beyond the face Four abstract poster presentations highlighting clinical applications and results of Sofwave’s SUPERB™ non-invasive medical aesthetic technology will also be on exhibit SAN CLEMENTE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- ...

 PRESS RELEASE

Sofwave’s SUPERB™ Non-Invasive Skin Treatment Technology Receives Regu...

Sofwave’s SUPERB™ Non-Invasive Skin Treatment Technology Receives Regulatory Clearance in Japan Significantly Expanding its Coverage of the APAC Region Japan represents third largest non-surgical medical aesthetic market in the world SAN CLEMENTE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has granted the Company approval to commercially market Sofwave’s SUPERB™ Technology. Market appr...

 PRESS RELEASE

Sofwave to Participate in Upcoming Conferences

Sofwave to Participate in Upcoming Conferences SAN CLEMENTE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the following conferences: 24th Annual Needham Virtual Healthcare ConferencePresentation Format: Corporate overviewPresentation Date: Wednesday, April 9, 2025Presentation Time: 9:30 a.m. ETWebcast: Wells Fargo 2025 Virtual Private MedTech...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch